糖尿病性ケトアシドーシス市場- 世界の産業規模、動向、機会、予測、2018年～2028年治療別、エンドユーザー別、地域別、競合別分析

糖尿病性ケトアシドーシスの世界市場規模は2022年に32億4,000万米ドルとなり、2028年までのCAGRは5.35%で、予測期間中に力強い成長が予測されています。

世界の糖尿病性ケトアシドーシス（DKA）市場は、主に世界の糖尿病有病率の増加に牽引され、ヘルスケア産業の中でもダイナミックで急速に発展している分野です。糖尿病性ケトアシドーシスは、血糖値の上昇と血液中のケトン体の存在を特徴とする糖尿病の重篤な合併症であり、迅速かつ効果的な治療を行わなければ生命を脅かす結果につながる可能性があります。この市場には、DKAエピソードの管理と予防を目的とした医薬品、診断薬、医療機器、治療プロトコールなどが含まれます。

DKA世界市場の成長を促進する主な要因の一つは、糖尿病、特にDKAに罹患しやすい1型糖尿病の罹患率の上昇です。ライフスタイルの変化、座りがちな生活習慣、食事パターンなどが世界中で糖尿病患者の急増に寄与しており、DKAは医療従事者にとっても患者にとっても大きな関心事となっています。DKA市場では薬物療法が重要な役割を果たしており、インスリン療法はDKA管理の要となっています。超速効型インスリン製剤や高度なデリバリーシステムなどの新しいインスリン製剤の開発により、DKA治療の有効性と利便性が向上しています。さらに、DKAの基礎となる代謝異常に対処するための新しい薬理学的薬剤の発見に研究努力が注がれています。

診断ツールや技術もDKA市場の重要な構成要素であり、DKAの早期発見とモニタリングを可能にしています。持続グルコースモニタリングシステム、ポイント・オブ・ケア型ケトン体検査装置、高度血糖測定器は、患者やヘルスケア専門家に糖尿病をより効果的に管理し、DKAエピソードを予防する力を与えています。さらに、インスリンポンプや輸液セットのような医療機器市場は、DKA管理のためのインスリン投与の精度と容易さを向上させ、大きな技術革新を目の当たりにしています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の糖尿病性ケトアシドーシス市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療法別（インスリン療法、電解質補充、輸液補充）
  • エンドユーザー別（病院・クリニック、外来診療センター、その他）
  • 地域別
  • 企業別（2022年）
• 市場マップ
  • 治療別
  • エンドユーザー別
  • 地域別

第5章 アジア太平洋地域の糖尿病性ケトアシドーシス市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療別
  • エンドユーザー別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の糖尿病性ケトアシドーシス市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療別
  • エンドユーザー別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の糖尿病性ケトアシドーシス市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療別
  • エンドユーザー別
  • 国別
• 北米国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の糖尿病性ケトアシドーシス市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの糖尿病性ケトアシドーシス市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療別
  • エンドユーザー別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 糖尿病性ケトアシドーシスの世界市場SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Novo Nordisk AS
• Baxter Healthcare Corporation
• B. Braun Medical Inc.
• ICU Medical, Inc.
• Pfizer Inc.
• Merit Pharmaceutical
• SteriCare Solutions
• Soxa Formulations & Research（Pvt.）Ltd
• BD company
• Fresenius Kabi USA

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Diabetic Ketoacidosis Market has valued at USD 3.24 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 5.35% through 2028. The Global Diabetic Ketoacidosis (DKA) Market is a dynamic and rapidly evolving sector within the healthcare industry, primarily driven by the increasing prevalence of diabetes worldwide. Diabetic Ketoacidosis is a severe complication of diabetes characterized by elevated blood sugar levels and the presence of ketones in the blood, which can lead to life-threatening consequences if not treated promptly and effectively. This market encompasses a range of pharmaceuticals, diagnostics, medical devices, and treatment protocols aimed at managing and preventing DKA episodes.

One of the key factors propelling the growth of the Global DKA Market is the rising incidence of diabetes, particularly Type 1 diabetes, which is more susceptible to DKA. Lifestyle changes, sedentary habits, and dietary patterns have contributed to the surge in diabetes cases across the globe, making DKA a major concern for healthcare providers and patients alike. Pharmaceutical interventions play a crucial role in the DKA market, with insulin therapy being the cornerstone of DKA management. The development of novel insulin formulations, such as ultra-rapid-acting insulins and advanced delivery systems, has improved the efficacy and convenience of DKA treatment. Additionally, research efforts are focused on discovering new pharmacological agents to address the underlying metabolic abnormalities in DKA.

Diagnostic tools and technologies are another vital component of the DKA market, enabling early detection and monitoring of the condition. Continuous glucose monitoring systems, point-of-care ketone testing devices, and advanced blood glucose meters have empowered patients and healthcare professionals to manage diabetes more effectively and prevent DKA episodes. Moreover, the market for medical devices like insulin pumps and infusion sets has witnessed significant innovation, enhancing the precision and ease of insulin administration for DKA management.

Key Market Drivers

Rising Prevalence of Diabetes

The Global Diabetic Ketoacidosis (DKA) Market is experiencing a significant boost due to the rising prevalence of diabetes worldwide. Diabetes has reached epidemic proportions, with millions of individuals affected globally, and this growing patient population is a key driver behind the increasing demand for DKA management solutions. According to the International Diabetes Federation (IDF), approximately 537 million people were living with diabetes in 2021, and this number is projected to reach a staggering 643 million by 2030. Among these individuals, those with Type 1 diabetes are particularly susceptible to DKA, a life-threatening complication.

The surge in diabetes cases can be attributed to a variety of factors, including changes in lifestyle, unhealthy dietary habits, sedentary lifestyles, and genetic predispositions. Urbanization and the adoption of Western diets high in sugar and processed foods have also contributed to the global diabetes epidemic. As more people are diagnosed with diabetes, the risk of DKA episodes increases, making effective DKA management and prevention crucial.

This rising prevalence of diabetes has led to greater awareness and recognition of the importance of timely intervention and treatment for DKA. Patients and healthcare providers are increasingly vigilant about monitoring blood glucose levels, recognizing the signs and symptoms of DKA, and implementing preventative measures. As a result, there is a growing demand for pharmaceuticals, diagnostics, medical devices, and educational resources aimed at addressing DKA within the broader context of diabetes care.

Increasing Awareness and Education

Increasing awareness and education are pivotal factors propelling the growth of the Global Diabetic Ketoacidosis (DKA) Market. As diabetes continues to rise globally, there has been a concerted effort to educate both healthcare professionals and the general public about the risks and complications associated with this chronic condition, particularly in the context of DKA. Public health campaigns, patient advocacy groups, and healthcare organizations have been instrumental in spreading knowledge about diabetes and its life-threatening complications, such as DKA. These initiatives have emphasized the importance of early diagnosis, regular blood glucose monitoring, and the need for prompt medical intervention in case of suspected DKA. By creating awareness, they have empowered individuals with diabetes and their caregivers to recognize the warning signs of DKA, which include excessive thirst, frequent urination, abdominal pain, and confusion.

Healthcare professionals, including doctors, nurses, and educators, have also benefited from increased awareness and education about DKA. Continuous medical education programs and guidelines provide clinicians with the latest evidence-based practices for managing and preventing DKA. This improved knowledge among healthcare providers has led to quicker and more accurate diagnoses, as well as more effective treatment strategies. Furthermore, the role of technology in educating and raising awareness about DKA cannot be overstated. Online resources, mobile applications, and social media platforms have become invaluable tools for disseminating information about diabetes and its complications. Patients can access information about DKA prevention, treatment options, and lifestyle management with ease, leading to improved self-management and better outcomes. As awareness and education efforts continue to expand, there is a corresponding increase in demand for products and services related to DKA management.

Innovations in Insulin Delivery

Innovations in insulin delivery have emerged as a significant driver of growth in the Global Diabetic Ketoacidosis (DKA) Market. The way insulin is administered plays a pivotal role in diabetes management, and recent advancements in this field have not only improved the convenience of treatment but also reduced the risk of DKA episodes.

Traditional insulin delivery methods, such as insulin injections, have been gradually supplemented and, in some cases, replaced by cutting-edge alternatives. One such innovation is the advent of insulin pumps, which offer continuous subcutaneous insulin infusion. These devices provide a more precise and consistent delivery of insulin throughout the day, closely mimicking the natural insulin secretion of a healthy pancreas. By maintaining stable blood glucose levels, insulin pumps help reduce the incidence of hyperglycemia, a key trigger for DKA. Furthermore, insulin pumps are equipped with sophisticated features like bolus calculators, which assist users in calculating the correct insulin dose based on factors such as carbohydrate intake and current glucose levels. This feature helps prevent insulin underdosing, which can lead to uncontrolled hyperglycemia and, consequently, DKA.

Smart insulin pens are another noteworthy innovation. These devices not only simplify insulin administration but also offer features such as dose memory, which helps users keep track of their insulin doses, reducing the risk of double dosing or missed doses. Some smart pens are even compatible with mobile apps that enable users to monitor their insulin usage and glucose levels conveniently, promoting better glycemic control and DKA prevention. Additionally, advanced insulin delivery systems are integrating predictive algorithms and artificial intelligence to provide users with personalized insulin dosing recommendations. These algorithms consider various factors, including current glucose levels, carbohydrate intake, physical activity, and historical data to suggest optimal insulin doses. By minimizing the risk of both hypoglycemia and hyperglycemia, these innovations contribute significantly to DKA risk reduction.

Key Market Challenges

Limited Access to Healthcare Services

In many low-income and underserved areas, access to healthcare services is severely restricted. This limitation includes a lack of medical facilities, healthcare professionals, and essential medical supplies. Individuals in these regions often struggle to obtain even the most basic diabetes care, such as regular blood glucose monitoring or insulin therapy.

Delayed diagnosis and inadequate glycemic control are common consequences of limited access to healthcare. Without timely intervention and appropriate treatment, individuals with diabetes are at a significantly higher risk of developing DKA. This life-threatening condition can lead to hospitalizations, complications, and even fatalities.

The financial burden of healthcare further exacerbates the problem. Many people in these regions cannot afford the high costs associated with diabetes management, which include insulin, glucose monitoring devices, and regular medical check-ups. This financial barrier forces individuals to make difficult choices, sometimes sacrificing essential diabetes care to meet other basic needs.

Financial Barriers

Financial barriers are a significant impediment to the effective management and prevention of Diabetic Ketoacidosis (DKA) within the Global DKA Market. Insulin, a life-saving medication for individuals with diabetes, can be prohibitively expensive in many parts of the world. The cost of insulin varies widely depending on the type and brand, and for those without adequate health insurance, it can create a substantial financial burden. This financial strain can lead to rationing of insulin or even skipping doses, increasing the risk of DKA.

In addition to insulin, essential diabetes-related supplies such as glucose monitoring devices, test strips, and insulin delivery systems can also be costly. These devices are integral to effective diabetes management and DKA prevention, but their high prices can deter individuals from acquiring them. As a result, many people may resort to less accurate or less frequent glucose monitoring, potentially missing critical warning signs of DKA.

High out-of-pocket expenses for healthcare services and medications can lead to non-compliance with treatment regimens. Individuals who struggle to afford their medications or regular medical appointments are more likely to have poor glycemic control, making them more susceptible to DKA. This creates a vicious cycle, as uncontrolled diabetes can result in complications that require additional healthcare expenditures.

Key Market Trends

Technological Advancements in Glucose Monitoring

Technological advancements in glucose monitoring have emerged as a pivotal driver of growth in the Global Diabetic Ketoacidosis (DKA) Market. These innovations are revolutionizing diabetes management by providing individuals with diabetes and healthcare professionals with powerful tools to monitor and control blood glucose levels more effectively. Continuous Glucose Monitoring (CGM) systems, in particular, have been instrumental in reshaping the landscape of DKA prevention and management.

CGM systems offer real-time and continuous data on glucose levels, allowing users to track fluctuations and trends throughout the day and night. By providing immediate feedback on the impact of diet, exercise, medication, and other factors, CGMs empower individuals with diabetes to make informed decisions regarding insulin dosing and carbohydrate intake. This level of precision helps maintain stable blood glucose levels and significantly reduces the risk of hyperglycemia, a key trigger for DKA. Moreover, CGM technology offers several key advantages, such as alerts for high and low glucose levels, trend analysis, and historical data review. These features aid in the early detection of hyperglycemia, enabling timely intervention to prevent DKA. For instance, CGM systems can alert users when glucose levels are approaching dangerous thresholds, prompting them to take corrective action, such as adjusting insulin dosages or consuming carbohydrates.

The user-friendliness of CGMs, along with their wireless connectivity to smartphones and other digital devices, has made glucose monitoring more convenient and accessible. Data from CGMs can be easily shared with healthcare providers, allowing for remote monitoring and timely adjustments to treatment plans. This level of connectivity enhances the collaborative effort between patients and healthcare professionals, resulting in better glycemic control and reduced DKA risk.

Health Data Integration and Artificial Intelligence in Glucose Monitoring

Health data integration and artificial intelligence (AI) in glucose monitoring are emerging as powerful drivers of growth in the Global Diabetic Ketoacidosis (DKA) Market. These technologies are transforming diabetes care by providing more comprehensive insights into glycemic control and predictive capabilities that are crucial for DKA prevention and management.

Health data integration involves the seamless collection, aggregation, and analysis of patient data from various sources, such as continuous glucose monitors (CGMs), insulin pumps, electronic health records (EHRs), and mobile health apps. By consolidating this diverse data, healthcare providers gain a holistic view of a patient's diabetes management, facilitating more informed decisions.

AI algorithms play a central role in making sense of this vast and complex dataset. These algorithms can analyze historical glucose patterns, dietary habits, physical activity levels, medication adherence, and even environmental factors to provide real-time insights and predictions. AI-powered glucose monitoring systems can anticipate fluctuations in blood glucose levels, allowing individuals with diabetes to proactively manage their condition. For example, AI algorithms can predict the impact of meals on blood glucose levels, helping users make informed dietary choices and insulin dosing decisions. They can also identify trends and patterns that may indicate impending hyperglycemia, allowing for early intervention and DKA prevention.

Segmental Insights

Treatment Insights

Based on the Treatment, Insulin therapy emerged as the dominant segment in the global market for Global Diabetic Ketoacidosis Market in 2022. The primary reason for this is that insulin is the cornerstone of DKA management. DKA is characterized by elevated blood sugar levels and the presence of ketones in the blood, and insulin is the only treatment that directly addresses these underlying issues.

End User Insights

Based on the End User, the Hospitals and Clinics segment emerged as the dominant player in the global market for Global Diabetic Ketoacidosis Market in 2022. The primary reason for this preference is rooted in the severity of DKA episodes and the need for immediate and comprehensive medical care. DKA episodes can occur at any time, and they often require continuous monitoring and adjustments to treatment regimens. Hospitals and clinics provide round-the-clock healthcare services, ensuring that patients receive the necessary care and attention at any hour, which is crucial for managing DKA effectively.

Regional Insights

North America emerged as the dominant player in the global Diabetic Ketoacidosis Market in 2022, holding the largest market share. North America, particularly the United States and Canada, has one of the highest prevalence rates of diabetes in the world. The increasing incidence of diabetes, including both Type 1 and Type 2 diabetes, directly contributes to a larger population at risk of DKA. This high prevalence drives the demand for DKA-related products and services.

Technological advancements in glucose monitoring, insulin delivery systems, and electronic health records have significantly improved the quality of care for individuals with diabetes and DKA. These innovations not only enhance patient outcomes but also drive market growth.

Key Market Players

• Novo Nordisk AS

• Baxter Healthcare Corporation

• B. Braun Medical Inc.

• ICU Medical, Inc.

• Pfizer Inc.

• Merit Pharmaceutical

• SteriCare Solutions

• Soxa Formulations & Research (Pvt.) Ltd

• BD company

• Fresenius Kabi USA

Report Scope:

In this report, the Global Diabetic Ketoacidosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Diabetic Ketoacidosis Market, By Treatment:

• Insulin Therapy
• Electrolyte Replacement
• Fluid Replacement

Global Diabetic Ketoacidosis Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Global Diabetic Ketoacidosis Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Ketoacidosis Market.

Available Customizations:

• Global Diabetic Ketoacidosis Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Diabetic Ketoacidosis Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Treatment (Insulin Therapy, Electrolyte Replacement, Fluid Replacement)
  • 4.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 4.2.3. By Region
  • 4.2.4. By Company (2022)
• 4.3. Market Map
  • 4.3.1. By Treatment
  • 4.3.2. By End User
  • 4.3.3. By Region

5. Asia Pacific Diabetic Ketoacidosis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment
  • 5.2.2. By End User
  • 5.2.3. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Diabetic Ketoacidosis Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Treatment
      • 5.3.1.2.2. By End User
  • 5.3.2. India Diabetic Ketoacidosis Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Treatment
      • 5.3.2.2.2. By End User
  • 5.3.3. Australia Diabetic Ketoacidosis Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Treatment
      • 5.3.3.2.2. By End User
  • 5.3.4. Japan Diabetic Ketoacidosis Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Treatment
      • 5.3.4.2.2. By End User
  • 5.3.5. South Korea Diabetic Ketoacidosis Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Treatment
      • 5.3.5.2.2. By End User

6. Europe Diabetic Ketoacidosis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Diabetic Ketoacidosis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By End User
  • 6.3.2. Germany Diabetic Ketoacidosis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By End User
  • 6.3.3. Spain Diabetic Ketoacidosis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By End User
  • 6.3.4. Italy Diabetic Ketoacidosis Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Treatment
      • 6.3.4.2.2. By End User
  • 6.3.5. United Kingdom Diabetic Ketoacidosis Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Treatment
      • 6.3.5.2.2. By End User

7. North America Diabetic Ketoacidosis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Diabetic Ketoacidosis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By End User
  • 7.3.2. Mexico Diabetic Ketoacidosis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By End User
  • 7.3.3. Canada Diabetic Ketoacidosis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By End User

8. South America Diabetic Ketoacidosis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Diabetic Ketoacidosis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By End User
  • 8.3.2. Argentina Diabetic Ketoacidosis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By End User
  • 8.3.3. Colombia Diabetic Ketoacidosis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By End User

9. Middle East and Africa Diabetic Ketoacidosis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Diabetic Ketoacidosis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By End User
  • 9.3.2. Saudi Arabia Diabetic Ketoacidosis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By End User
  • 9.3.3. UAE Diabetic Ketoacidosis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By End User
  • 9.3.4. Egypt Diabetic Ketoacidosis Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Treatment
      • 9.3.4.2.2. By End User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Diabetic Ketoacidosis Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Novo Nordisk AS
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Baxter Healthcare Corporation
• 14.3. B. Braun Medical Inc.
• 14.4. ICU Medical, Inc.
• 14.5. Pfizer Inc.
• 14.6. Merit Pharmaceutical
• 14.7. SteriCare Solutions
• 14.8. Soxa Formulations & Research (Pvt.) Ltd
• 14.9. BD company
• 14.10. Fresenius Kabi USA

15. Strategic Recommendations

16. About Us & Disclaimer